Baron Capital Exits Apogee Therapeutics (APGE) Following AbbVie Buyout
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here.
Apogee Therapeutics Inc. (APGE)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Remedium Capital Partners David Hawkins | 586,691 | $77,871,496 | +1% | 17.24% |
| 2. | Alpine Associates Robert Emil Zoellner | 57,900 | $7,685,067 | 0.48% | |
| 3. | Bayforest Capital Theodoros Tsagaris | 2,674 | $354,920 | -56% | 0.33% |
| 4. | Walleye Capital Will England | 1,659 | $220,199 | 0% | |
| 5. | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $49.85 | 12,500 | $623,125.00 | 20,000 | 2024-12-12 | Filing | |
| $49.02 | 7,500 | $367,650.00 | 7,500 | 2024-12-12 | Filing | |
| $17.00 | 1,750,000 | $29,750,000.00 | 1,750,000 | 2023-07-13 | Filing | |
| $17.00 | 892,529 | $15,172,993.00 | 892,529 | 2023-07-13 | Filing | |
| $17.00 | 1,992,734 | $33,876,478.00 | 1,992,734 | 2023-07-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $134.17 | 5,500 | $737,935.00 | 168,498 | 2026-08-05 | Filing | |
| $133.63 | 20,000 | $2,672,600.00 | 995,987 | 2026-07-08 | Filing | |
| $132.74 | 5,500 | $730,070.00 | 177,873 | 2026-07-01 | Filing | |
| $132.60 | 26,400 | $3,500,640.00 | 179,248 | 2026-06-22 | Filing | |
| $132.54 | 80,000 | $10,603,200.00 | 1,015,987 | 2026-06-22 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,507,032 | $730,948,292 | 0.01% | |
| 2. | 2,297,743 | $304,979,428 | 0.01% | |
| 3. | 289,464 | $38,420,557 | 0.01% | |
| 4. | 152,815 | $20,283,070 | 0% | |
| 5. | 121,258 | $16,094,574 | 0.02% |
News See All
3 Best ETFs With 50%+ Upside to Buy in August 2026, According to Analysts
Analysts see a few thematic ETFs that stand out this August for investors seeking long‑run growth in digital assets and healthcare. These include t...
10 Stocks Paying Off Big Time
Ten stocks kicked off the trading week with strong gains, bucking a lackluster performance on the broader market, thanks to a flurry of positive industry news that spilled over to their stocks.
12 Best High Short Interest Stocks With Highest Upside Potential
On May 29, Melissa Brown, Managing Director of Investment Decision Research, joined BNN Bloomberg to assess the health of the US economy.
Billionaire Joe Edelman's 10 Stock Picks with Huge Upside Potential
Joseph Edelman, the billionaire chief of New York-based Perceptive Advisors, specializes in the biotechnology and life sciences sectors.
Wedbush Raises Price Target on Apogee Therapeutics (APGE)
On March 3, Wedbush increased its price target on Apogee Therapeutics Inc. (NASDAQ:APGE) from $90 to $95.
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds
On February 5, J.P. Morgan shared its views on trends that are expected to define healthcare in 2026.
End of Apogee (APGE) Drug Collaboration Leads to Revised Analyst Expectations
Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the 13 hot stocks to buy with the highest upside potential. On February 2, Jefferies lowered its price target on Apogee Therapeutics Inc.
13 Hot Stocks to Buy with the Highest Upside Potential
On average, equities are expected continue to deliver positive results in 2026, this time with greater breadth across sectors, styles, and regions, compared to the other periods of the recent bull market...
Here is Why Apogee Therapeutics (APGE) Appears Attractive
Selloff in Apogee Therapeutics (APGE) stock, following the release of Sanofi’s Phase 3 amlitelimab data, is viewed as a market overreaction by Meacham.
Hedge Fund Resource Center